Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 15.36B P/E - EPS this Y 15.00% Ern Qtrly Grth -
Income -175.01M Forward P/E -79.56 EPS next Y 93.70% 50D Avg Chg -7.00%
Sales 2.61B PEG -0.72 EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book 5.03 EPS next 5Y 98.50% 52W High Chg -16.00%
Recommedations 1.60 Quick Ratio 1.85 Shares Outstanding 184.77M 52W Low Chg 191.00%
Insider Own 1.00% ROA -2.71% Shares Float 183.44M Beta 1.27
Inst Own 98.45% ROE -5.60% Shares Shorted/Prior 16.42M/13.82M Price 85.13
Gross Margin 73.19% Profit Margin -6.70% Avg. Volume 1,843,972 Target Price 78.78
Oper. Margin -3.13% Earnings Date Oct 30 Volume 4,593,022 Change -11.73%
About Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation News
06:00 AM Exact Sciences to Participate in J.P. Morgan Healthcare Conference
12/12/24 Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?
12/06/24 Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?
12/05/24 Exploring High Growth Tech Stocks in December 2024
11/26/24 Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
11/26/24 Exact Sciences to Participate in December Investor Conferences
11/25/24 Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
11/19/24 Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now
11/18/24 EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
11/16/24 Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock
11/15/24 Exact Sciences showcases early cancer detection test data at AACR meeting
11/13/24 Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
11/11/24 Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
11/08/24 Exact Sciences’ forecast cut shocks analysts
11/07/24 Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
11/07/24 Exact Sciences Third Quarter 2024 Earnings: Misses Expectations
11/06/24 Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
11/06/24 Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
11/06/24 Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
11/06/24 Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
EXAS Chatroom

User Image Woodman7 Posted - 1 day ago

$EXAS - 2025 is going to be the best year ever for EXAS! Way undervalued based on current offerings and a full pipeline of new opportunities coming soon! LFG! 🥂🥂

User Image Woodman7 Posted - 12/30/24

@bearcreekzeke - yes! So many catalyst coming up it’s surprising it’s hanging in the 50s. $EXAS

User Image Woodman7 Posted - 12/30/24

$EXAS - I was looking at the revenue numbers and trends last night. The large reduction in the 2024 Outlook was almost all from a take down of a very optimistic (backend loaded) 4Q plan/forecast. Very little was due to 3Q underachievement. Now, the call for 4Q is (imho) too low off of trends and normal seasonalization. The avg analyst call is $695 for the qtr, which would bring the total year rev to $2.741b in line with EXAS full year Outlook. That would represent only a 7% increase from 4Q23 and is less than 3Q24 of $709m. (2Q and 3Q ran approximately 13% higher than the respective 2023 qtrs) I know the rationale for the drop was hurricane impacts and slower than expected pick up in sales from new reps, etc. But I would be surprised if they would tolerate a qtr originally forecast at $777m coming in that light. They need at least $700m to bring full year in at +10% growth over 2023. I’ll look at this somemore but I do think they will over-achieve the $695m expectation.

User Image julianjakobi Posted - 12/30/24

$BLGO - $EXAS $INND "Detailed DD on Exceptional BioLargo Opportunity" Attention investors! I've published an extensive Reddit DD on BioLargo - an exceptional buying opportunity. As a fellow investor, I'm eager to share this detailed analysis. BioLargo has innovative technologies addressing critical challenges. My research uncovered key factors - strong advantages, promising growth drivers, and positive milestones - making this attractive. I encourage you to review the full DD to understand BioLargo's business, growth potential, and positioning. This is an opportunity I'm excited about, which is why I wanted to share it, including with a friend interested in BioLargo. I believe the company's unique value proposition and fundamentals make it worthy of your consideration. I welcome your feedback. Please review the DD and let me know your thoughts. Let's explore this exceptional BioLargo opportunity together. https://www.reddit.com/r/BioLargo/s/8WKAWip3Ll

User Image NVDAMillionaire Posted - 12/24/24

$EXAS Exact Sciences Corporation (EXAS): A Comprehensive Cancer Diagnostics Leader Navigating the Future https://beyondspx.com/article/exact-sciences-corporation-exas-a-comprehensive-cancer-diagnostics-leader-navigating-the-future

User Image Woodman7 Posted - 12/23/24

@bearcreekzeke - nope. Pretty much just a straight up 45 and over commercial. $EXAS

User Image Woodman7 Posted - 12/23/24

$EXAS - Cologuard commercial on MNF! Too bad it’s such a lopsided game..

User Image BullYa Posted - 12/23/24

$EXAS looks like it wants back to $50 🧐

User Image Woodman7 Posted - 12/23/24

@Kleeno - I still don’t get why this is the preferred standard. I would never want to do a colonoscopy procedure again. $EXAS makes it so simple..(and free!) $QQQ

User Image Kleeno Posted - 12/23/24

$EXAS So… a friend posts this pic of her husband on FB. 25 hours of prep. 🤦🏻‍♂️… enjoy the next 25 hours. LOL

User Image steven1x Posted - 12/23/24

$EXAS interesting , is this a buyout target? https://stocktwits.com/steven1x/message/597564523

User Image Woodman7 Posted - 12/21/24

$EXAS - Too expensive and dangerous. Screen with Cologuard. $EXAS $QQQ

User Image Woodman7 Posted - 12/21/24

$EXAS - https://www.yahoo.com/news/went-colonoscopy-bill-19-000-143737567.html

User Image bearcreekzeke Posted - 12/20/24

$EXAS Let's all get LOW and drop that #2 and get this stock price back UP! https://youtu.be/ILMHqj2JAh4?si=YGkm1LgbvHmkU_GR

User Image CDNroadwarrior Posted - 12/19/24

@bearcreekzeke Thank you. I hope it holds too. Just watch for the market to hold, $585 is a key level for the SPY. If SPY fails then all bets are off. I like $EXAS and I hope the company does well, but I try not to fall in love with my stocks.

User Image Kleeno Posted - 12/18/24

$EXAS Oh boy.... can never get a break. Next Endorsement??? https://www.yahoo.com/news/lil-wayne-chris-brown-marshmello-190158620.html

User Image Kleeno Posted - 12/18/24

$EXAS I’m thinking shit gonna hit fan market wide… Forest River, RV manufacturer by me just had another round of layoffs…. More than double the last round a few months ago. That was happening last time recession hit. 🤦🏻‍♂️. Too bad Joe didn’t swing by the factories when he was out here for a wedding, and tell the workers how he’s fixed everything back in October.

User Image CDNroadwarrior Posted - 12/18/24

$EXAS I am hoping the $56 ish level will act as support. Most people who purchased this year got in around $61. Those who bought since this summer have an average price of $53.50, which I would use as a stop. It is hitting its 50dma and the RSI is right in the middle of the range. The latest price target is from BofA at $72 which is the upside target for my trade. Chime in with thoughts.

User Image CDNroadwarrior Posted - 12/18/24

$EXAS We are starting to fill in that gap (down to $56) and I am starting to buy a couple of shares back.

User Image ManyThanks212 Posted - 12/18/24

$EXAS

User Image Anecdotal Posted - 12/17/24

@Kleeno $EXAS that will be a long journey against the seed oil industry, followed by more years of playing out better colon health.

User Image Woodman7 Posted - 12/16/24

$EXAS - just saw another article about colon cancer increases in other countries as well. This is a huge world-wide health industry issue and unfortunately (or fortunately for $EXAS ) there just aren’t enough gastroenterologists to support the need for colonoscopies. Non-invasive screening needs to be extended to other ages and areas and strongly encouraged by PCP’s et Al. $QQQ

User Image Ford150 Posted - 12/16/24

$EXAS another one we trade actively on technicals. Main purpose is accumulation, this will be a good o e in the future. Holding 1.2k shares currently.

User Image Kleeno Posted - 12/16/24

$EXAS Seed Oils… Bad. While unfortunately good for business. Popular cooking ingredient linked to cancer diagnoses in young people https://www.foxnews.com/video/6366061171112

User Image Anecdotal Posted - 12/13/24

@Kleeno gotta have a little sense of humor. $EXAS

User Image bearcreekzeke Posted - 12/13/24

$EXAS This morning's selloff on LOW LOW LOW volume. Lil Jon Youtube ad now has over ONE MILLION views. Hey Exact Sciences marketing department - GET THOSE LIL JON COMMERCIALS ROLLING on TV! https://youtu.be/ILMHqj2JAh4?si=0DEw_c_pG-j0ay7C

User Image ChartLaboratory_com Posted - 12/12/24

$HIMX - Himax Technologies, Inc. 🚀 Current Price: $9.71 🔑 Support: $6.08 | Resistance: $9.80 🔥 Williams %R: Overbought but strong momentum ⚡️ Strategy: Momentum trade above $9.80 for breakout continuation 💥 Join for More Insights: www.patreon.com/chartlab 💥 70% OFF Black Friday Sale 🖤 💬 Available on Reddit: ChartLaboratory #StocksToWatch #Momentum #TechStocks #TradeSmart $ALK - Alaska Air Group, Inc. 📉 Current Price: $63.42 🔑 Support: $47.66 | Resistance: $65.62 📊 MACD: Positive, slight weakening ⚡️ Strategy: Swing trade above $64.00 for continuation 💥 Join for More Insights: www.patreon.com/chartlab 💥 💬 Available on Reddit: ChartLaboratory #StocksToWatch #SwingTrade #Airlines #TradeSmart $EXAS - Exact Sciences Corporation 📉 Current Price: $62.51 🔑 Support: $48.02 | Resistance: $64.55 📊 MACD: Weakening but still positive ⚡️ Strategy: Scalp trade above $63.00 💥 Join for More Insights: www.patreon.com/chartlab 💥

User Image bearcreekzeke Posted - 12/12/24

$EXAS Pump it up Lil John!!! https://www.cologuard.com/getlow2

User Image bearcreekzeke Posted - 12/12/24

$EXAS Leerink Partners raises target price to $95 from $70. Wow! A lot of people must be dropping those drawers - Get Low #2! https://youtu.be/ILMHqj2JAh4?si=JIgF-_rUAPynoZt6

User Image investorjustin Posted - 12/11/24

$EXAS when will the buyout be??

Analyst Ratings
Evercore ISI Group Outperform Oct 1, 24
Raymond James Market Perform Sep 26, 24
Canaccord Genuity Buy Sep 13, 24
Piper Sandler Overweight Sep 12, 24
Wells Fargo Overweight Aug 27, 24
Benchmark Buy Aug 1, 24
Stifel Buy Aug 1, 24
Goldman Sachs Buy Jul 17, 24
Evercore ISI Group Outperform Jul 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Condella Sarah EVP, Human Resources EVP, Human Resources Jan 02 Sell 73.50 2,000 147,000 69,423 01/04/24
Baranick Brian Gen. Mgr., Precision.. Gen. Mgr., Precision Oncology Jan 02 Sell 73.50 879 64,606 7,992 01/04/24
Condella Sarah EVP, Human Resources EVP, Human Resources Dec 14 Sell 70.00 2,000 140,000 71,423 12/18/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Sell 66.49 13,007 864,835 37,909 10/13/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Option 0 27,504 50,916 10/13/23
Herriott James General Counsel General Counsel Feb 14 Sell 65.59 400 26,236 9,095 02/16/23
Herriott James General Counsel General Counsel Feb 14 Option 0 883 9,495 02/16/23
Condella Sarah EVP, Human Resources EVP, Human Resources Feb 14 Sell 65.59 954 62,573 85,166 02/16/23
Condella Sarah EVP, Human Resources EVP, Human Resources Feb 14 Option 0 2,030 86,120 02/16/23
ORVILLE JACOB A General Manager, Scr.. General Manager, Screening Feb 14 Sell 69.59 954 66,389 16,114 02/16/23
ORVILLE JACOB A General Manager, Scr.. General Manager, Screening Feb 14 Option 0 2,030 17,068 02/16/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Sell 31.37 16,872 529,275 18,654 10/13/22
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Option 0 35,006 35,526 10/13/22
Zanotti Katherine S Director Director Jun 30 Sell 40.13 1,086 43,581 60,318 07/01/22
Doyle James Edward Director Director Jun 07 Option 16.52 3,000 49,560 42,830 06/08/22
Doyle James Edward Director Director Mar 17 Option 16.52 10,000 165,200 39,830 03/18/22
Conroy Kevin T President and CEO President and CEO Mar 17 Option 23.92 236,622 5,659,998 1,167,606 03/18/22
Conroy Kevin T President and CEO President and CEO Feb 28 Option 0 29,887 945,283 03/02/22
Conroy Kevin T President and CEO President and CEO Feb 28 Sell 76.69 14,299 1,096,590 930,984 03/02/22
COWARD D SCOTT Chief Legal Officer Chief Legal Officer Feb 28 Option 0 8,288 20,146 03/02/22
COWARD D SCOTT Chief Legal Officer Chief Legal Officer Feb 28 Sell 76.69 3,912 300,011 16,234 03/02/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 28 Option 0 8,462 23,178 03/02/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 76.69 4,050 310,594 19,128 03/02/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 23 Option 0 10,197 92,894 02/25/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 23 Sell 70.1 4,717 330,662 88,177 02/25/22
Conroy Kevin T President and CEO President and CEO Feb 23 Option 0 58,643 942,522 02/25/22
Conroy Kevin T President and CEO President and CEO Feb 23 Sell 70.1 27,126 1,901,533 915,396 02/25/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 23 Option 0 12,747 17,673 02/25/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 23 Sell 70.1 5,815 407,631 11,858 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 23 Option 0 12,747 20,613 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 23 Sell 70.1 5,897 413,380 14,716 02/25/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 23 Option 0 10,197 19,754 02/25/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 23 Sell 70.1 4,717 330,662 15,037 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 22 Option 0 3,112 9,423 02/24/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 22 Sell 69.05 1,557 107,511 7,866 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 22 Option 0 2,247 83,821 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 22 Sell 69.05 1,124 77,612 82,697 02/24/22
Conroy Kevin T President and CEO President and CEO Feb 22 Sell 69.05 5,188 358,231 883,879 02/24/22
Conroy Kevin T President and CEO President and CEO Feb 22 Option 0 10,373 889,067 02/24/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 22 Option 0 2,247 10,682 02/24/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 22 Sell 69.05 1,125 77,681 9,557 02/24/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 22 Option 0 2,247 6,035 02/24/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 22 Sell 69.05 1,109 76,576 4,926 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 14 Option 78.33 2,030 159,010 82,512 02/16/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 14 Sell 79.55 938 74,618 81,574 02/16/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 14 Option 78.33 3,972 311,127 8,150 02/16/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 14 Sell 79.55 1,839 146,292 6,311 02/16/22
Conroy Kevin T President and CEO President and CEO Feb 14 Option 32.74 222,316 7,278,626 893,103 02/16/22
Conroy Kevin T President and CEO President and CEO Feb 14 Sell 79.55 14,409 1,146,236 878,694 02/16/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 14 Option 78.33 2,030 159,010 7,475 02/16/22